​
​

Avalo Therapeutics (AVTX) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Avalo Therapeutics Revenue Highlights

Latest Revenue (Y)

$1.41M

0

Main Segment (Y)

Product

Avalo Therapeutics Revenue by Period

Avalo Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$1.41M-92.20%
2022-12-31$18.05M234.40%
2021-12-31$5.40M-19.42%
2020-12-31$6.70M-0.76%
2019-12-31$6.75M-63.17%
2018-12-31$18.33M-34.11%
2017-12-31$27.81M2312.24%
2016-12-31$1.15M100.00%
2015-12-31-100.00%
2014-12-31-100.00%
2013-12-31--

Avalo Therapeutics generated $1.41M in revenue during NA 2023, up -92.20% compared to the previous quarter, and up 7.68% compared to the same period a year ago.

Avalo Therapeutics Revenue by Quarter

DateRevenueChange
2024-06-30-100.00%
2024-03-31--100.00%
2023-12-31$571.00K141.95%
2023-09-30$236.00K-63.30%
2023-06-30$643.00K35.37%
2023-03-31$475.00K-46.99%
2022-12-31$896.00K-94.01%
2022-09-30$14.95M1347.14%
2022-06-30$1.03M-11.94%
2022-03-31$1.17M435.62%
2021-12-31$219.00K-83.78%
2021-09-30$1.35M-59.76%
2021-06-30$3.35M609.30%
2021-03-31$473.00K-68.39%
2020-12-31$1.50M34.70%
2020-09-30$1.11M-16.97%
2020-06-30$1.34M-51.42%
2020-03-31$2.75M-131.57%
2019-12-31$-8.72M-255.41%
2019-09-30$5.61M26.16%
2019-06-30$4.45M-17.78%
2019-03-31$5.41M8.57%
2018-12-31$4.98M22.32%
2018-09-30$4.07M-14.84%
2018-06-30$4.79M6.74%
2018-03-31$4.48M100.70%
2017-12-31$2.23M-91.08%
2017-09-30$25.04M15766.66%
2017-06-30$157.80K-58.93%
2017-03-31$384.21K111.10%
2016-12-31$182.00K-43.39%
2016-09-30$321.50K-50.58%
2016-06-30$650.49K100.00%
2016-03-31-100.00%
2015-12-31-100.00%
2015-09-30-100.00%
2015-06-30-100.00%
2015-03-31-100.00%
2014-12-31-100.00%
2014-09-30-100.00%
2014-06-30-100.00%
2014-03-31--

Avalo Therapeutics generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Avalo Therapeutics Revenue Breakdown

Avalo Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
License$516.00K$14.69M$625.00K-$100.00K
Product$1.41M$3.36M$4.77M$6.70M-
Sales Force Revenue-----
Sales Revenue, Product----$6.65M
Prescription Drugs----$6.65M

Avalo Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (73.18%), and License (26.82%).

Quarterly Revenue by Product

Product/ServiceSep 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Sep 19Jun 19Mar 19Dec 18Sep 18
Product$249.00K$54.00K$236.00K$643.00K$475.00K$726.00K$432.00K$1.03M$1.17M$219.00K$1.35M$2.73M$473.00K$1.50M$1.11M-----
License---$170.00K$14.52M---$625.00K-$100.00K---------
Sales Force Revenue------------------$159.18K-
Prescribed Dietary Supplements---------------$2.32M$1.80M$1.79M$1.91M$2.10M
Prescription Drugs---------------$3.19M$2.65M$3.62M$2.91M$1.98M
Sales Revenue, Product---------------$5.51M$4.45M$5.41M$4.82M$4.07M
Grant Revenue--------------------

Avalo Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (100.00%).

Avalo Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
ACLXArcellx$110.32M$26.03M
ANABAnaptysBio$17.16M$30.02M
MOLNMolecular Partners$7.04M$2.74M
IPSCCentury Therapeutics$2.23M$791.00K
AVTXAvalo Therapeutics$1.41M-
VRAXVirax Biolabs Group$8.56K$76.50K
ANEBAnebulo Pharmaceuticals--
CGEMCullinan Oncology--
GPCRStructure Therapeutics--
ALXOALX Oncology--
BNOXBionomics--
CCCCC4 Therapeutics--
AVTEAerovate Therapeutics--
BNTCBenitec Biopharma--
ACRVAcrivon Therapeutics--
PMVPPMV Pharmaceuticals--
MLYSMineralys Therapeutics--
ALZNAlzamend Neuro--
EWTXEdgewise Therapeutics--

AVTX Revenue FAQ

What is Avalo Therapeutics’s yearly revenue?

Avalo Therapeutics's yearly revenue for 2023 was $1.41M, representing a decrease of -92.20% compared to 2022. The company's yearly revenue for 2022 was $18.05M, representing an increase of 234.40% compared to 2021. AVTX's yearly revenue for 2021 was $5.4M, representing a decrease of -19.42% compared to 2020.

What is Avalo Therapeutics’s quarterly revenue?

Avalo Therapeutics's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a -100.00% decrease year-over-year (Q1 2023). AVTX's quarterly revenue for Q4 2023 was $571K, a 141.95% increase from the previous quarter (Q3 2023), and a -36.27% decrease year-over-year (Q4 2022).

What is Avalo Therapeutics’s revenue growth rate?

Avalo Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -73.92%, and for the last 5 years (2019-2023) was -79.14%.

What are Avalo Therapeutics’s revenue streams?

Avalo Therapeutics's revenue streams in c 23 are License, and Product. License generated $516K in revenue, accounting 26.82% of the company's total revenue, down -96.49% year-over-year. Product generated $1.41M in revenue, accounting 73.18% of the company's total revenue, down -58.15% year-over-year.

What is Avalo Therapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Avalo Therapeutics was Product. This segment made a revenue of $1.41M, representing 73.18% of the company's total revenue.